Literature DB >> 22945757

IPH-926 lobular breast cancer cells harbor a p53 mutant with temperature-sensitive functional activity and allow for profiling of p53-responsive genes.

Matthias Christgen1, Monika Noskowicz, Charlotte Heil, Elisa Schipper, Henriette Christgen, Robert Geffers, Hans Kreipe, Ulrich Lehmann.   

Abstract

Profiling of p53-responsive genes has been carried out in different cellular models, most of which involved genetic modifications or cytotoxic stimulation. We report on the utilization of IPH-926 human lobular breast cancer cells for the profiling of p53-responsive genes using a novel approach without such modifications. We discovered that IPH-926 cells harbor a homozygous TP53 missense mutation encoding for a rare p53 mutant (E285K) with temperature-sensitive (ts) loss of function characteristics. This mutation had evolved as a late, secondary genetic event during the natural clonal evolution of the corresponding lobular carcinoma. In vitro temperature shifts reconstituted endogenous wild-type p53 activity in IPH-926, as evidenced by induction of p21(Waf1). Transcriptional alterations associated with restored p53 function were profiled using Affymetrix microarrays and a new strategy to gate out non-specific temperature effects. At the P=0.0005 significance level, 60 genes were differentially expressed following reconstitution of p53 activity. These genes included CDKN1A, MDM2 and PHLDA3, a recently described p53-inducible inhibitor of AKT. Similar transcriptional alterations were observed upon reconstitution of p53 activity in BT-474 cells, which also harbor ts-p53 E285K, and in ASPC1 cells transduced with ts-p53 A138V. Consistent with these models, low PHLDA3 expression was associated with nuclear p53 accumulation, indicative of deleterious TP53 mutations, in primary breast cancers. From a molecular point of view, IPH-926 thus provides a new tool to study transcriptional programs controlled by p53. From a tumor pathology perspective, IPH-926 also provides the first direct evidence of a p53-related clonal evolutionary pathway in lobular breast cancer progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22945757     DOI: 10.1038/labinvest.2012.126

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  14 in total

1.  An In Silico Analysis Identified Members of the Pleckstrin Homology-Like Domain, Family B (PHLDB family) as Potential Prognostic and Predictive Biomarkers of Treatment Response in Breast Cancer Patients.

Authors:  Renan Gomes do Nascimento; Jéssica de Moraes; Danilo de Oliveira Cerqueira; Sandro Jorge Januário
Journal:  Eur J Breast Health       Date:  2022-07-01

2.  IPH-926 lobular breast cancer cells are triple-negative but their microarray profile uncovers a luminal subtype.

Authors:  Matthias Christgen; Robert Geffers; Hans Kreipe; Ulrich Lehmann
Journal:  Cancer Sci       Date:  2013-12       Impact factor: 6.716

Review 3.  High frequency of lobular breast cancer in distant metastases to the orbit.

Authors:  Mieke Raap; Wiebke Antonopoulos; Maximilian Dämmrich; Henriette Christgen; Diana Steinmann; Florian Länger; Ulrich Lehmann; Hans Kreipe; Matthias Christgen
Journal:  Cancer Med       Date:  2014-10-30       Impact factor: 4.452

4.  Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells.

Authors:  Ton van Agthoven; Lambert C J Dorssers; Ulrich Lehmann; Hans Kreipe; Leendert H J Looijenga; Matthias Christgen
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

5.  Is upregulation of BCL2 a determinant of tumor development driven by inactivation of CDH1/E-cadherin?

Authors:  Inga Karch; Elisa Schipper; Henriette Christgen; Hans Kreipe; Ulrich Lehmann; Matthias Christgen
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

6.  Lobular breast cancer: molecular basis, mouse and cellular models.

Authors:  Matthias Christgen; Patrick W B Derksen
Journal:  Breast Cancer Res       Date:  2015-02-08       Impact factor: 6.466

7.  Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature.

Authors:  Marta Lionetti; Marzia Barbieri; Martina Manzoni; Sonia Fabris; Cecilia Bandini; Katia Todoerti; Filomena Nozza; Davide Rossi; Pellegrino Musto; Luca Baldini; Antonino Neri
Journal:  Oncotarget       Date:  2016-04-19

8.  Investigating DNA Binding and Conformational Variation in Temperature Sensitive p53 Cancer Mutants Using QM-MM Simulations.

Authors:  Shruti Koulgi; Archana Achalere; Uddhavesh Sonavane; Rajendra Joshi
Journal:  PLoS One       Date:  2015-11-18       Impact factor: 3.240

9.  AGO2 involves the malignant phenotypes and FAK/PI3K/AKT signaling pathway in hypopharyngeal-derived FaDu cells.

Authors:  Yanhui Zhang; Baoxin Wang; Xinwei Chen; Weidong Li; Pin Dong
Journal:  Oncotarget       Date:  2017-05-22

10.  Immunohistochemical correlates of TP53 somatic mutations in cancer.

Authors:  Balázs Murnyák; Tibor Hortobágyi
Journal:  Oncotarget       Date:  2016-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.